LMR Partners’s Pacific Biosciences PACB Stock Holding History

LMR Partners’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,146,928	Closed	-$6.94M	–	494
2019 Q2	$6.94M	Sell	1,146,928 -833,722	-42%	-$5.85M	0.25%	54
2019 Q1	$14.3M	Buy	1,980,650 +155,650	+9%	+$1.13M	0.73%	30
2018 Q4	$13.5M	Buy	+1,825,000	New	+$11.6M	0.66%	32
2014 Q2	–	Sell	-21,406	Closed	-$114K	–	526
2014 Q1	$114K	Buy	+21,406	New	+$135K	0.02%	253

Other funds holding PACB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

KLCMU

Kite Lake Capital Management (UK) London, United Kingdom $125M AUM 198.01% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

LMR Partners's PACB Position: Q3 2019 in Review

LMR Partners sold out of Pacific Biosciences (PACB) in Q3 2019, closing a stake of 1,146,928 shares — an estimated $6.94M sold.

LMR Partners first reported a position in PACB in Q1 2014 and held it in 4 quarters. The position peaked at $14.3M in Q1 2019. 148 funds tracked by Wall St. Rank hold PACB as of Q3 2019.

LMR Partners reported no remaining Pacific Biosciences position as of Q3 2019 after selling out during the quarter.
LMR Partners sold 1,146,928 Pacific Biosciences shares in Q3 2019, an estimated $6.94M.
LMR Partners first reported a position in Pacific Biosciences in Q1 2014 and held it in 4 quarters.
LMR Partners's Pacific Biosciences position peaked at $14.3M in Q1 2019.
148 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2019.

Based on LMR Partners's 13F filing for Q3 2019, filed 14 Nov 2019.